Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionStandard Life Aberdeen plc
Latest Disclosed Ownership233,480 shares
Latest Disclosed Value $ 104,258,160
Standard Life Aberdeen plc reports 10.90% decrease in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On April 29, 2026 - Standard Life Aberdeen plc filed a 13F-HR form disclosing ownership of 233,480 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $104,258,159 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 16, 2026 disclosing 262,057 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of -10.90% during the quarter. The current value of the position is $104,325,868 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-29 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 233,480 -28,577 -10.90 104,258 -12.25 0.0913
2026-01-16 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 262,057 -52,832 -16.78 118,806 -3.66 0.1839
2025-11-07 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 314,889 26,922 9.35 123,323 -3.81 0.1951
2025-07-24 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 287,967 -16,747 -5.50 128,203 -12.68 0.2181
2025-05-13 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 304,714 -42,856 -12.33 146,828 5.32 0.2863
2025-01-24 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 347,570 -23,519 -6.34 139,410 -19.32 0.2617
2024-10-25 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 371,089 -313 -0.08 172,790 -0.74 0.3168
2024-08-09 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 371,402 -202,795 -35.32 174,084 -27.47 0.3337
2024-05-09 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 574,197 -6,821 -1.17 240,020 1.53 0.4706
2024-01-31 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 581,018 384,730 196.00 236,410 246.35 0.5125
2023-11-07 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 196,288 -837 -0.42 68,257 -1.60 0.1742
2024-06-20 2023-06-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 197,125 -1,760 -0.88 69,370 10.71 0.1614
2023-08-04 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 197,125 -1,760 69,370 0.1614
2024-06-20 2023-03-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 198,885 15,069 8.20 62,663 18.05 0.1568
2023-04-28 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 198,885 15,069 62,663 0.1568
2024-06-20 2022-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 183,816 -2,999 -1.61 53,082 -1.87 0.1443
2023-02-10 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 183,816 -2,999 53,082 0.1443
2022-11-10 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 186,815 80,841 76.28 54,091 81.51 0.1610
2022-08-05 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 105,974 9,591 9.95 29,801 18.72 0.0937
2022-05-04 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 96,383 1,760 1.86 25,102 20.80 0.0642
2022-02-10 2021-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 94,623 -420,216 -81.62 20,780 -77.98 0.0456
2022-02-08 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 94,623 -420,216 20,780 0.0150
2021-11-15 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 514,839 -12,600 -2.39 94,349 -11.30 0.2126
2021-08-10 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 527,439 430,311 443.03 106,367 409.44 0.2330
2021-05-06 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 97,128 6,845 7.58 20,879 -2.15 0.0475
2021-02-10 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 90,283 3,165 3.63 21,337 -10.00 0.0520
2020-10-21 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 87,118 -12,406 -12.47 23,707 -17.99 0.0633
2020-08-10 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 99,524 -1,549 -1.53 28,908 20.20 0.0783
2020-05-13 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 101,073 -24,504 -19.51 24,050 -12.53 0.0764
2020-02-18 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 125,577 -1,876 -1.47 27,495 27.33 0.0664
2019-11-13 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 127,453 -54,111 -29.80 21,593 -35.15 0.0538
2019-08-13 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 181,564 -108,875 -37.49 33,296 -37.68 0.0739
2019-05-14 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 290,439 -431,610 -59.78 53,426 -54.47 0.1158
2019-02-12 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 722,049 -164,557 -18.56 117,336 -31.34 0.2785
2018-11-20 2018-09-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 886,606 -258,307 -22.56 170,889 -12.21 0.3185
2018-11-13 2018-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 886,606 -258,307 170,889
2018-08-09 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,144,913 807,086 238.91 194,646 253.50 0.3740
2018-05-15 2018-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 337,827 170,495 101.89 55,063 119.57 0.1092
2018-02-12 2017-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 167,332 95,825 134.01 25,078 130.64 0.0480
2017-11-14 2017-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 71,507 71,507 10,873 0.0198
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.